Investors & Media

Press Releases

Press Releases

Date Title View
Toggle Summary Sage Therapeutics to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 20, 2021-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast
View HTML
Toggle Summary Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022
Following the pre-NDA meeting, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD The planned initial submission package will be for the treatment of MDD with an anticipated PPD filing thereafter
View HTML
Toggle Summary Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychopharmacology (ECNP) Congress
Improvement in measurements of overall quality of life, functioning and general well-being achieved at Day 15 and sustained at Day 42 Consistent and differentiated safety and tolerability profile seen across clinical programs Sage to host conference call on October 4, 2021 at 8:00am ET CAMBRIDGE,
View HTML
Toggle Summary Sage Therapeutics Launches SageCitizen Social Impact Initiative
Effort embodies Sage’s long-term commitment to investing in People, Patients, Planet and Community CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 1, 2021-- Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of
View HTML
Toggle Summary Sage Therapeutics Appoints Chris Benecchi as Chief Commercial Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 21, 2021-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced the appointment of Chris Benecchi
View HTML
Toggle Summary Sage Therapeutics Receives Fast Track Designation for SAGE-718 for the Treatment of Huntington’s Disease
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 15, 2021-- Sage Therapeutics, Inc. (Nasdaq:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the U.S.
View HTML
Toggle Summary Sage Therapeutics to Present at the Morgan Stanley Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 2, 2021-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will
View HTML
Toggle Summary Sage Therapeutics to Present at Upcoming August Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 4, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will present
View HTML
Toggle Summary Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
Announced positive topline data from pivotal WATERFALL Study of zuranolone in patients with MDD showing statistically significant and clinically meaningful reduction in depressive symptoms at Day 15, primary endpoint Continued pipeline expansion and acceleration advancing all three brain health
View HTML
Toggle Summary Sage Therapeutics to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 20, 2021-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast
View HTML